Viatris Inc. (NASDAQ: VTRS), a frontrunner in global healthcare, has unveiled a series of divestitures in its business framework. Leading the announcements, Viatris is set to gather gross proceeds of up to $6.94 billion, netting around $5.2 billion after deducting associated costs. Details on Divested Units and Financial Implications: The company’s decision to divest primarily […]
Granules India has secured approval for its abbreviated new drug application (ANDA) for Venlafaxine Hydrochloride Extended-Release (ER) Capsules USP, 37.5 mg, 75 mg, and 150 mg from the US Food and Drug Administration (FDA). Venlafaxine ER Capsules is bioequivalent to Upjohn US 2’s Effexor XR Extended-Release Capsules, said the Indian pharma company. Venlafaxine HCl extended-release […]
Marksans Pharma has secured final approval for its abbreviated new drug application (ANDA) for Pregabalin Capsules from the US Food & Drugs Administration (FDA). The approval is for the 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg strengths of Pregabalin Capsules. It is indicated in relieving pain […]
The US Federal Trade Commission (FTC) has granted conditional approval for Dutch pharma company Mylan’s acquisition of Upjohn, the off-patent branded and generic established medicines business of Pfizer. The deal was announced in July 2019 with an objective to create a new global pharma company through the merger of Mylan and Upjohn, which will be […]